Chemotherapy of human small-cell gastrointestinal carcinoma xenografts in nude mice. 1995

K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
First Department of Surgery, Niigata University School of Medicine, Japan.

We established two xenografts of small-cell carcinoma (SCC) arising in the oesophagus or the stomach, designated TEG13 and TSG15, and investigated the responses to experimental chemotherapy on these strains. Both tumours were classified as the intermediate cell type of SCC composed of small cells having neuroendocrine features in terms of morphology, argyrophil property, and immunoreactivity for neuron-specific enolase. Mitomycin C, cisplatin, and cyclophosphamide were judged to be effective against both strains. Particularly, cisplatin produced almost complete regression of tumour growth of the TEG13 strain. Etoposide proved effective only against the TSG15 strain. Moreover, the combined treatment with etoposide and cisplatin produced the most pronounced antitumour effect against the TSG15 strain. These studies suggest that cisplatin may be a key drug for chemotherapy of oesophageal SCC, and etoposide plus cisplatin treatment may be especially recommended in the treatment of gastric SCC. Mitomycin C should be re-evaluated in gastrointestinal SCC.

UI MeSH Term Description Entries
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus

Related Publications

K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
January 1991, Cancer research,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
February 2002, Chinese medical journal,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
January 1987, NCI monographs : a publication of the National Cancer Institute,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
January 1980, Human pathology,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
November 1977, Cancer,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
July 1988, The Laryngoscope,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
January 1987, In vivo (Athens, Greece),
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
November 2000, Zhonghua yi xue za zhi,
K Aizawa, and N Tanaka, and H Yabusaki, and S Suzuki, and I Muto, and T Nishimaki, and T Suzuki, and K Hatakeyama, and O Tanaka
July 2001, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!